CN107744413A - The preparation method of new Valved allograft - Google Patents
The preparation method of new Valved allograft Download PDFInfo
- Publication number
- CN107744413A CN107744413A CN201710868914.3A CN201710868914A CN107744413A CN 107744413 A CN107744413 A CN 107744413A CN 201710868914 A CN201710868914 A CN 201710868914A CN 107744413 A CN107744413 A CN 107744413A
- Authority
- CN
- China
- Prior art keywords
- preparation
- valve
- bovine
- pipeline
- new
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2415—Manufacturing methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2418—Scaffolds therefor, e.g. support stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Manufacturing & Machinery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to a kind of preparation method of new Valved allograft, characterized in that, the new Valved allograft includes vascular canal, valve and junction, the valve is connected by junction with vascular canal, it is complete that this method both ensure that extra vascular was fixed, the native state of blood vessel is in turn ensure that, not fold, non-warping knotting, beneficial to surgical stapling, anticalcium, it is anti-aging, hence it is evident that to improve long-term postoperative.
Description
Technical field
The present invention relates to a kind of blood vessel, and in particular to a kind of preparation method of new Valved allograft, belongs to medical bio material
Expect technical field.
Background technology
China's congenital heart disease rate is about 0.6-0.9%, occupies the first place of inborn defect, and annual new hair congenital heart disease is suffered from
Youngster about 15 ~ 200,000, and for existing children with CHD more than 2,000,000, wherein Complexed Congenital Heart Disease accounts for 20%.Quite a few
Complexed Congenital Heart Disease lesion involves right ventricular outflow, such as serious tetralogy of Fallot, complete transposition of great arteries, common
Truncus artiriosus, double outlet of right ventricle and pulmonary atresia etc..The whether perfect of pulmonary valve 26S Proteasome Structure and Function is one important
Problem, it directly affects the late result of patient.However, chronic pulmonary incompetence is often that this kind of patient is postoperative most common
The problem of, due to the presence of chronic volume load, it can finally cause that sufferer exercise tolerance is poor, ECG-QRS Wave is broadening with heart rate
The problems such as disorderly and sudden death incidence increase.Therapeutic intervention as early as possible can effectively prevent right ventricle from irreversible fibrosis occurs,
Development for symptom management is significant.Established using valved conduit or recovery right ventricular outflow-pulmonary artery is continuous
Property, it is one of ordinary operation of the above-mentioned heart malformations of surgical correction, is widely used to many complexity Congenital Hearts at present
Sick right ventricular outflow tract reconstruction and Ross operation（Rose's operation）In.
The species and performance of the clinical efficacy of right ventricular outflow tract reconstruction art and its selected valved conduit material are closely related.
Existing polytype valved conduit material sequential use was in clinic, including synthetic material pipeline, porcine aortic valve or lung in the past
Arterial valve pipeline, pericardium pipeline etc., due to being limited by the limitation of material in itself, existing valved conduit is difficult to fully meet clinic
Demand, if valved homograft is since Ross takes the lead in applying, existing 50 years history simultaneously achieve good effect, and different
The valved conduits such as kind allosome animal sustainer, pulmonary artery, jugular vein are also applied to clinic, but Conduit valved homograft source has
Limit, two kinds of valved conduit sizes be not easy to match and easily calcification, decay, validity period is limited etc. have impact on curative effect and limit
Clinical practice；Because right heart system pressure is low, VPV is slow, and artificial valve particularly mechanical prosthetic valve inserts rear anti-freezing problem complications
Height, it is set to be very limited in the clinical practice of children's congenital heart disease.In recent years, bovine jugular vein is because having natural three flaps knot
Structure, anti-reflux be functional, the advantages that being adapted to the human body right side to feel concerned about the environment under low pressure of system, source abundance and be increasingly becoming department of cardiac surgery
Outflow tract of right ventricle rebuilds one of alternative materials, and Medtronic Inc. of the U.S. fixes bovine jugular vein using conventional cross-linking agent glutaraldehyde and formed
Contegra pipelines, be currently the only to obtain U.S. FDA（Food and medicine Surveillance Authority of the U.S.）Ox neck of the approval into market
Vein valved conduit product.But because China fails at home always to the limiting factor of ox source biological products overseas, the product
Apply in market.But more and more clinical practices recently in the recent period show that Contegra pipelines equally exist tube wall calcification at a specified future date, distal end
The problems such as anastomotic stricture and pipeline Ectasia cause pipeline to decay.
Above-mentioned complication may be relevant with glutaraldehyde processing, and glutaraldehyde has lacking for its own as foreign material crosslinking agent
Fall into.Have it is now recognized that glutaraldehyde cross-linking is fixed the main reason for causing biomaterial easy calcification：1）Biomaterial is lost after crosslinking
Great amount of soluble albumen, its surface exposure amino acid aldehyde radical can induce calcium crystallization formation, and make phosphoric acid, atriphos,
The effect that proteoglycan etc. suppresses calcification is destroyed；2）Glutaraldehyde cross-linking can damage cells normal calcium regulation mechanism, cause calcium
Ion is accumulated in the cell, and the fragment of dead cell and lipid can turn into the starting core of calcification；3）After glutaraldehyde processing still
There is a unpaired carboxyl, carboxyl contained by amino acid is easiest to be combined with calcium salt in biomaterial collagen, along with glutaraldehyde processing
Cytotoxicity afterwards, vascular endothelial cell is set to be difficult to growth covering, collagenous fibres exposure；4）The cell toxicant of glutaraldehyde free aldehyde
Property can also induce inflammatory cell chemotactic, cause chronic inflammatory cell infiltration, promote local calcium deposition.Those skilled in the art
Member has attempted to scheme and solves the technical problem, but the problem is never well solved.
The content of the invention
The present invention is exactly for technical problem present in prior art, there is provided a kind of new Valved allograft and preparation side
Method, this method both ensure that extra vascular was fixed completely, and in turn ensure that the native state of blood vessel, not fold, and non-warping knotting is sharp
It is anti-aging in surgical stapling, anticalcium, hence it is evident that to improve long-term postoperative.
To achieve these goals, technical scheme is as follows, a kind of preparation method of new Valved allograft, and it is special
Sign is, the new Valved allograft includes vascular canal 1, valve 2 and shaping ring 3, the valve 2 by shaping ring 3 with
Vascular canal 1 connects.Shaping ring 3 causes valve mutually to be fixed with vascular canal.
As a modification of the present invention, the material of the vascular canal is bovine pericardial tissue, is made by bovine pericardium,
The bovine pericardial tissue, which obtains, to be comprised the following steps：
（1）It is tissue-derived：Select ox age 2-4 year, health, the ox of free from infection；The source of ox may be selected to include buffalo, ox,
Yak；(source is regular, refuses unlawful killing)
（2）Collection of specimens：Complete to take out bovine pericardial tissue, the pericardial tissue removed is rinsed, will washed repeatedly with physiological saline immediately
Net blood vessel, which is put into preserve in the physiological saline for fill 4 DEG C -10 DEG C, is transported to laboratory, and period of storage is strict controlled in 3 hours
It is interior；
（3）Trimming screening：The fat and connective tissue of pericardial surface are removed, by lesion, there are the pericardiums such as the partially thin thickness partially of scar, thickness
Eliminate；
（4）To step（3）Bovine pericardial tissue after middle trimming screening carries out advanced treating.
As a modification of the present invention, the step（4）Middle advanced treating is specific as follows：
（41）De- cell：Bovine pericardium is placed in 1% Trition X-100 buffer solutions, 4 DEG C are incubated vibration 1 hour, PBS balances
Liquid cleans 3 times, 1 hour every time, is subsequently placed in the sonicator equipped with distilled water, ultrasonic frequency 20kHz, by instrument
Device power setting is 135kW, and work 5min, PBS equilibrium liquids oscillation cleaning 1 hour；
（42）It is fixed：Bovine pericardium is placed in the glutaraldehyde solution that concentration is 0.5-1.0%, pH value is 5.0-8.0 and soaked, is soaked
Temperature is 4-25 DEG C, and soak time is 2 days；
（43）Crosslinking：Bovine pericardium is placed in the OPC solution that concentration is 0.5%, 37 DEG C of shaking tables are crosslinked 72 hours；
（44）Rinse：Bovine pericardium is placed in the PBS solution containing 0.5mg/ml liquaemins, PBS is used after handling 30min at room temperature
Solution rinses 3 times, each 15min.
As a modification of the present invention, the vascular canal is formed by the bovine pericardium sewing after advanced treating, blood
Pipeline is cylinder, and bovine pericardium is cut into rectangular configuration, and long side doubling suture, suture is double-decker.Overlapping width
For 3mm, the special interlocking suture 2 of 7-0 sutures, special interlocking sutures 2 sutures and ensures that any section cutting will not release；
As a modification of the present invention, the vascular canal length is 30mm-180mm, and length seriation, 10mm is an area
Between；The a diameter of 10mm-22mm of vascular canal knot, diameter length seriation, 2mm are a section.
As a modification of the present invention, the valve application pericardium piece builds valve structure.
As a modification of the present invention, the valve is three valve structures, and three leaflets are semicircle three-dimensional structure,
It is fixed on by shaping ring on pipeline；The girth of three leaflets is more than cross-section of pipeline girth, and the three valves position that crosses is in pipeline length
Axle point midway, three valves are the contact of face and non-dots；Ring length of shaping is equal with cross-section of pipeline girth, with the three of pipeline girth
/ mono- is diameter, is cut in the long side of rectangle pericardium piece, continuously goes divided by pipeline girth 1/3rd is diameter
Three semicircular structures so that the semicircular indentations long back gauge 3mm of perigee distance original rectangle after cutting, be shaping ring
Bottom；Pericardium piece between gathering breach upwardly extends, length 3mm, is the extension of shaping ring.Shaping ring is by leaflet structure
It is fixed on inside pipeline, suture suture shaping ring extension, bottom, valve are fixed on vascular wall, the suture of adjacent petals blade root
The length of leaflet diameter 1/10.Shaping ring plays a part of stable valve.
As a modification of the present invention, the suture passes through shaping ring extension, bottom, sutures valve and tube wall,
Valve is fixed on vascular wall, the length of adjacent petals blade root suture leaflet diameter 1/10, stable valve, ensure when valve is closed without
Backflow.
Relative to prior art, the invention has the advantages that, 1）A kind of new Valved allograft described in the technical scheme
Preparation method, wherein going cellular processes to remove cell for ultrasonic combined Trition X-100.It is to adopt that tradition, which goes the method for cell,
With detergent such as Trition X-100, SDS etc., long action time be present, there is organelle residual in sample.It is ultrasonic combined
Trition X-100 go cell to overcome the defects of going cellular processes to be confined to chemical reagent in the past；2）Institute in the technical scheme
A kind of preparation method of new Valved allograft is stated, wherein organization material source is wide, and the optional leeway of blood vessel diameter, length is big, with
The matching degree of Different age pediatric patient is very good；3）A kind of preparation method of new Valved allograft described in the technical scheme, wherein
The crosslinking agent of vascular canal is fixed from glutaraldehyde, then carries out OPC modification.OPC is that a kind of flavonoids is more
Phenol, the fruit, bark and seed of many plants are widely present in, itself does not have toxicity, is natural antioxidant, is used as the heart
Vasoprotectant.It also has antibacterial, anti-inflammatory, antitumor and other effects, and has potential anti-calcification.The friendship of OPC
Connection effect is that hydrogen bond is formed between phenolic hydroxyl group and stromatin amidocarbonylation, mainly with the proline that is rich in collagen it
Between form hydrogen bond.OPC is for the elastin laminin in matrix also crosslinking effect, because elastin laminin also contains dried meat ammonia in itself
Acid or hydroxyproline, OPC easily combine to form hydrogen bond with elastin laminin, so as to play stabilization to elastin laminin.It is former
The hydrogen bond formed between anthocyanidin and collagen and elastin laminin may be to maintain natural structure and improve the main of tensile strength
Factor；4）The technical scheme organization material source is wide, cost is relatively low, is easy to further popularization and application, the popularization of the program and
Have great importance using for effectively treatment congenital heart disease.
Brief description of the drawings
Fig. 1 is a kind of overall structure diagram of new Valved allograft；
Fig. 2 is valve fixed structure schematic diagram；
Fig. 3 is shaping ring structural representation；
Fig. 4 is bovine pericardium structural representation；
Fig. 5 is overall structure stereogram of the present invention.
In figure：1st, vascular canal, 2, valve, 3, junction, 4, leaflet, 5, shaping ring, 6, suture, 7, bovine pericardium,
Embodiment：
In order to deepen the understanding of the present invention, the present embodiment is described in detail below in conjunction with the accompanying drawings.
Embodiment 1：Referring to Fig. 1-Fig. 5, a kind of preparation method of new Valved allograft, the new Valved allograft includes blood
Pipeline 1, valve 2 and junction 3, the valve 2 are connected by shaping ring 5 with vascular canal 1.Shaping ring 5 causes valve
It is connected with vascular canal.The material of the vascular canal is bovine pericardial tissue, is made by bovine pericardium 7, the bovine pericardium
Tissue acquisition comprises the following steps：（1）It is tissue-derived：Select ox age 2-4 year, health, the ox of free from infection；The source of ox is optional
Select including buffalo, ox, yak；(source is regular, refuses unlawful killing)；（2）Collection of specimens：It is complete to take out bovine pericardial tissue,
The pericardial tissue removed is rinsed repeatedly with physiological saline immediately, and clean blood vessel is put into and fills 4 DEG C -10 DEG C of physiological saline
Middle preservation is transported to laboratory, and period of storage was strict controlled in 3 hours；（3）Trimming screening：Remove pericardial surface fat and
Connective tissue, by lesion, there are the pericardiums such as the partially thin thickness partially of scar, thickness to eliminate；（4）To step（3）Ox after middle trimming screening
Pericardial tissue carries out advanced treating；The step（4）Middle advanced treating is specific as follows：
（41）De- cell：Bovine pericardium is placed in 1% Trition X-100 buffer solutions, 4 DEG C are incubated vibration 1 hour, PBS balances
Liquid cleans 3 times, 1 hour every time, is subsequently placed in the sonicator equipped with distilled water, ultrasonic frequency 20kHz, by instrument
Device power setting is 135kW, and work 5min, PBS equilibrium liquids oscillation cleaning 1 hour；
（42）It is fixed：Bovine pericardium is placed in the glutaraldehyde solution that concentration is 0.5-1.0%, pH value is 5.0-8.0 and soaked, is soaked
Temperature is 4-25 DEG C, and soak time is 2 days；
（43）Crosslinking：Bovine pericardium is placed in the OPC solution that concentration is 0.5%, 37 DEG C of shaking tables are crosslinked 72 hours；
（44）Rinse：Bovine pericardium is placed in the PBS solution containing 0.5mg/ml liquaemins, PBS is used after handling 30min at room temperature
Solution rinses 3 times, each 15min.
In the technical scheme, the vascular canal is formed by the bovine pericardium sewing after advanced treating, and vascular canal 1 is
Cylinder, bovine pericardium are cut into rectangular configuration, and long side doubling suture, suture is double-decker.Overlapping width is 3mm, 7-0
The special interlocking suture 2 of suture, special interlocking suture 2 sutures and ensure that any section cutting will not release；The blood vessel pipe
Road length is 30mm-180mm, and length seriation, 10mm is a section；The a diameter of 10mm-22mm of vascular canal knot, directly
Electrical path length seriation, 2mm are a section.
In the technical scheme, the valve is three valve structures, and three leaflets are semicircle three-dimensional structure, are consolidated by shaping ring 5
It is scheduled on pipeline；The girth of three leaflets 4 is more than cross-section of pipeline girth, and the three valves position that crosses is in pipeline major axis midpoint position
Put, three valves are the contact of face and non-dots；Shaping, ring length is equal with cross-section of pipeline girth, and 1/3rd with pipeline girth are
Diameter, cut in the long side of rectangle pericardium piece, continuously go divided by pipeline girth 1/3rd be diameter three and half
Circular configuration so that the semicircular indentations long back gauge 3mm of perigee distance original rectangle after cutting, be the bottom of shaping ring；Phase
Pericardium piece between poly- breach upwardly extends, length 3mm, is the extension of shaping ring.Leaflet structure is fixed on by shaping ring
Inside pipeline, suture suture shaping ring extension, bottom, valve are fixed on vascular wall, and adjacent petals blade root suture leaflet is straight
The length of footpath 1/10.Stable valve, ensure when valve is closed without backflowing.
It should be noted that above-described embodiment, is not used for limiting protection scope of the present invention, in above-mentioned technical proposal
On the basis of made equivalents or replacement each fall within the scope that the claims in the present invention are protected.
Claims (10)
1. a kind of preparation method of new Valved allograft, it is characterised in that the new Valved allograft includes vascular canal, valve
And junction, the valve are connected by junction with vascular canal, junction is the portion that valve mutually sutures with vascular canal
Position.
2. the preparation method of new Valved allograft according to claim 1, it is characterised in that the material of the valved conduit is
Bovine pericardial tissue, it is made by bovine pericardium,
The bovine pericardial tissue, which obtains, to be comprised the following steps：
（1）It is tissue-derived：Select ox age 2-4 year, health, the ox of free from infection；The source of ox may be selected to include buffalo, ox,
Yak；
（2）Collection of specimens：Complete to take out bovine pericardial tissue, the pericardial tissue removed is rinsed, will washed repeatedly with physiological saline immediately
Net blood vessel, which is put into preserve in the physiological saline for fill 4 DEG C -10 DEG C, is transported to laboratory, and period of storage is strict controlled in 3 hours
It is interior；
（3）Trimming screening：The fat and connective tissue of pericardial surface are removed, by lesion, there are the pericardiums such as the partially thin thickness partially of scar, thickness
Eliminate；
（4）To step（3）Bovine pericardial tissue after middle trimming screening carries out advanced treating.
3. the preparation method of new Valved allograft according to claim 2, it is characterised in that the step（4）Middle depth
Handle specific as follows：
（41）De- cell：Bovine pericardium is placed in 1% Trition X-100 buffer solutions, 4 DEG C are incubated vibration 1 hour, PBS balances
Liquid cleans 3 times, 1 hour every time, is subsequently placed in the sonicator equipped with distilled water, ultrasonic frequency 20kHz, by instrument
Device power setting is 135kW, and work 5min, PBS equilibrium liquids oscillation cleaning 1 hour；
（42）It is fixed：Bovine pericardium is placed in the glutaraldehyde solution that concentration is 0.5-1.0%, pH value is 5.0-8.0 and soaked, is soaked
Temperature is 4-25 DEG C, and soak time is 2 days；
（43）Crosslinking：Bovine pericardium is placed in the OPC solution i.e. grape seed extract that concentration is 0.5%, 37 DEG C of shaking tables are handed over
Connection 72 hours；
（44）Rinse：Bovine pericardium is placed in the PBS solution containing 0.5mg/ml liquaemins, PBS is used after handling 30min at room temperature
Solution rinses 3 times, each 15min;
Above-mentioned steps are carried out successively, it is therefore an objective to are removed immunogenicity, saved backup.
4. the preparation method of new Valved allograft according to claim 3, it is characterised in that the vascular canal is by passing through
Bovine pericardium sewing after advanced treating forms, and vascular canal is cylinder, and bovine pericardium is cut into rectangular configuration, and long side is to crease
Close, suture is double-decker.
5. the preparation method of new Valved allograft according to claim 4, it is characterised in that the vascular canal length is
30mm-180mm, length seriation, 10mm are a section；The a diameter of 10mm-22mm of vascular canal knot, diameter length system
Rowization, 2mm are a section.
6. the preparation method of new Valved allograft according to claim 5, it is characterised in that the valve application bovine pericardium
Piece builds valve structure.
7. the preparation method of new Valved allograft according to claim 6, it is characterised in that the valve is by leaflet group
Into, including three leaflet structures, three leaflets are semicircle three-dimensional structure, are fixed on by shaping ring on pipeline.
8. the preparation method of new Valved allograft according to claim 7, it is characterised in that the girth of three leaflets
More than cross-section of pipeline girth, and three valves position that crosses is in pipeline major axis point midway, and three leaflets are face and non-dots
Contact.
9. the preparation method of new Valved allograft according to claim 8, it is characterised in that sizing ring length is horizontal with pipeline
Perimeter of section is equal, with 1/3rd of pipeline girth for diameter, is cut in the long side of rectangle pericardium piece, continuous to remove
With 1/3rd of pipeline girth three semicircular structures for being diameter so that the semicircular indentations perigee distance after cutting is former
The long back gauge 3mm of rectangle, it is the bottom of shaping ring；Pericardium piece between gathering breach upwardly extends, length 3mm, a width of
1mm, it is the extension of shaping ring.
10. the preparation method of new Valved allograft according to claim 7, it is characterised in that the shaping ring is by leaflet
Structure is fixed on inside pipeline, and suture suture shaping ring extension, bottom, valve are fixed on vascular wall, adjacent petals blade root
Suture the length of leaflet diameter 1/10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710868914.3A CN107744413A (en) | 2017-09-22 | 2017-09-22 | The preparation method of new Valved allograft |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710868914.3A CN107744413A (en) | 2017-09-22 | 2017-09-22 | The preparation method of new Valved allograft |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107744413A true CN107744413A (en) | 2018-03-02 |
Family
ID=61254566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710868914.3A Pending CN107744413A (en) | 2017-09-22 | 2017-09-22 | The preparation method of new Valved allograft |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107744413A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107753152A (en) * | 2016-08-22 | 2018-03-06 | 北京市普惠生物医学工程有限公司 | Valve forming ring |
| CN108498869A (en) * | 2018-04-08 | 2018-09-07 | 中国医学科学院生物医学工程研究所 | Polyphenols crosslinking agent and its application in preparing anticalcium biovalve |
| CN108578781A (en) * | 2018-04-24 | 2018-09-28 | 中国医学科学院生物医学工程研究所 | Air bladder source biovalve material and the preparation method and application thereof |
| CN109172041A (en) * | 2018-11-21 | 2019-01-11 | 杭州嘉和众邦生物科技有限公司 | A kind of valved conduit and preparation method thereof |
| CN109330741A (en) * | 2018-11-21 | 2019-02-15 | 杭州嘉和众邦生物科技有限公司 | A kind of single-lobe pipeline and preparation method thereof |
| CN109549751A (en) * | 2018-11-21 | 2019-04-02 | 杭州嘉和众邦生物科技有限公司 | A kind of valved conduit and the method for making valved conduit |
| CN109567979A (en) * | 2018-11-21 | 2019-04-05 | 杭州嘉和众邦生物科技有限公司 | A kind of valved conduit and the method for making valved conduit |
| CN109893294A (en) * | 2019-03-20 | 2019-06-18 | 武汉杨森生物技术有限公司 | A kind of artificial blood vessel's valved conduit and preparation method thereof |
| CN110236733A (en) * | 2019-07-18 | 2019-09-17 | 南京市儿童医院 | A kind of novel valved conduit and preparation method thereof |
| CN110946855A (en) * | 2019-11-07 | 2020-04-03 | 浙江大学 | Application of procyanidine SA hydrogel in preparation of medicines for treating dystopy calcification |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1093566A (en) * | 1993-04-16 | 1994-10-19 | 成都科技大学 | Slow-calcifying compound epoxy cross-linking method for collagen tissue material |
| CN101444441A (en) * | 2008-12-31 | 2009-06-03 | 南京医科大学第一附属医院 | Support type artificial venous blood vessel with valve |
| CN204121199U (en) * | 2014-09-25 | 2015-01-28 | 北京迈迪顶峰医疗科技有限公司 | A kind of artificial bio-membrane is with valve blood vessel |
| CN105310797A (en) * | 2014-06-27 | 2016-02-10 | 尹宗涛 | Bionics artificial blood vessel with valvula |
| CN106473840A (en) * | 2016-12-07 | 2017-03-08 | 复旦大学附属儿科医院 | The mould and method of sewing of sewn by hand valved external conduit and pipeline sewing |
-
2017
- 2017-09-22 CN CN201710868914.3A patent/CN107744413A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1093566A (en) * | 1993-04-16 | 1994-10-19 | 成都科技大学 | Slow-calcifying compound epoxy cross-linking method for collagen tissue material |
| CN101444441A (en) * | 2008-12-31 | 2009-06-03 | 南京医科大学第一附属医院 | Support type artificial venous blood vessel with valve |
| CN105310797A (en) * | 2014-06-27 | 2016-02-10 | 尹宗涛 | Bionics artificial blood vessel with valvula |
| CN204121199U (en) * | 2014-09-25 | 2015-01-28 | 北京迈迪顶峰医疗科技有限公司 | A kind of artificial bio-membrane is with valve blood vessel |
| CN106473840A (en) * | 2016-12-07 | 2017-03-08 | 复旦大学附属儿科医院 | The mould and method of sewing of sewn by hand valved external conduit and pipeline sewing |
Non-Patent Citations (2)
| Title |
|---|
| 刘洋: "《原花青素处理去细胞牛心包细胞的相容性研究》", 《岭南心血管病杂志》 * |
| 张永生: "《超声联合曲拉通X-100制备猪去细胞的主动脉支架的研究》", 《南京医科大学硕士论文》 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107753152A (en) * | 2016-08-22 | 2018-03-06 | 北京市普惠生物医学工程有限公司 | Valve forming ring |
| CN108498869A (en) * | 2018-04-08 | 2018-09-07 | 中国医学科学院生物医学工程研究所 | Polyphenols crosslinking agent and its application in preparing anticalcium biovalve |
| CN108578781A (en) * | 2018-04-24 | 2018-09-28 | 中国医学科学院生物医学工程研究所 | Air bladder source biovalve material and the preparation method and application thereof |
| CN108578781B (en) * | 2018-04-24 | 2021-04-20 | 中国医学科学院生物医学工程研究所 | Swim bladder source biological valve material and preparation method and application thereof |
| CN109172041A (en) * | 2018-11-21 | 2019-01-11 | 杭州嘉和众邦生物科技有限公司 | A kind of valved conduit and preparation method thereof |
| CN109330741A (en) * | 2018-11-21 | 2019-02-15 | 杭州嘉和众邦生物科技有限公司 | A kind of single-lobe pipeline and preparation method thereof |
| CN109549751A (en) * | 2018-11-21 | 2019-04-02 | 杭州嘉和众邦生物科技有限公司 | A kind of valved conduit and the method for making valved conduit |
| CN109567979A (en) * | 2018-11-21 | 2019-04-05 | 杭州嘉和众邦生物科技有限公司 | A kind of valved conduit and the method for making valved conduit |
| CN109172041B (en) * | 2018-11-21 | 2024-03-12 | 杭州创心医学科技有限公司 | Valved pipeline and preparation method thereof |
| CN109330741B (en) * | 2018-11-21 | 2024-01-09 | 杭州创心医学科技有限公司 | Single-valve pipeline and manufacturing method thereof |
| CN109549751B (en) * | 2018-11-21 | 2024-01-09 | 杭州创心医学科技有限公司 | Valved conduit and method for manufacturing same |
| CN109893294B (en) * | 2019-03-20 | 2021-06-22 | 武汉杨森生物技术有限公司 | Artificial blood vessel valved pipeline and manufacturing method thereof |
| CN109893294A (en) * | 2019-03-20 | 2019-06-18 | 武汉杨森生物技术有限公司 | A kind of artificial blood vessel's valved conduit and preparation method thereof |
| CN110236733B (en) * | 2019-07-18 | 2021-06-04 | 南京市儿童医院 | Valved pipeline and preparation method thereof |
| CN110236733A (en) * | 2019-07-18 | 2019-09-17 | 南京市儿童医院 | A kind of novel valved conduit and preparation method thereof |
| CN110946855A (en) * | 2019-11-07 | 2020-04-03 | 浙江大学 | Application of procyanidine SA hydrogel in preparation of medicines for treating dystopy calcification |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107744413A (en) | The preparation method of new Valved allograft | |
| JP3739407B2 (en) | Heart valve replacement technology using flexible tubing | |
| US7905826B2 (en) | Methods for modifying vascular vessel walls | |
| US7387604B2 (en) | Methods for treating valve-associated regions of vascular vessels | |
| US20090254175A1 (en) | Valved stent for chronic venous insufficiency | |
| JPH07501465A (en) | Fetal membrane tube for nerve and vascular grafts | |
| Stelzer | The Ross procedure: state of the art 2011 | |
| JPH11503051A (en) | Peracetic acid cross-linked non-antigenic ICL graft | |
| US10568914B1 (en) | Human birth tissue laminate and methods of use | |
| CN107308496B (en) | Biological tissue reinforcing scaffold material and preparation method thereof | |
| CN104302245A (en) | Tissue-engineered heart valve for transcatheter repair | |
| JP2004502499A (en) | Biomaterials containing animal corneal tissue | |
| CN107412871A (en) | A kind of artificial bio-membrane's heart/blood vessel valve on basement membrane components top layer and preparation method thereof | |
| Yu et al. | Nonglutaraldehyde treated porcine pericardium with good biocompatibility, reduced calcification and improved Anti-coagulation for bioprosthetic heart valve applications | |
| RU2499612C2 (en) | Biological nasal bridge implant and method for making it | |
| RU2355327C2 (en) | Multivalvular mitral and aortic disease surgical correction combined with active infective endocarditis | |
| CA3138296A1 (en) | Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices | |
| US10226256B2 (en) | Methods for modifying vascular vessel walls | |
| CN109529120A (en) | A kind of small intestinal submucosa matrix repairs the preparation method of gel | |
| CN100443064C (en) | Preparation process of biological valve-possessed duct for pulmonary artery vessel restoration or reconstruction | |
| WO2017067295A1 (en) | Artificial biological blood vessel having valve and preparation method thereof | |
| JP7169645B2 (en) | Method for inactivating heterologous antigens in living tissue | |
| RU2202991C2 (en) | Extracardiac valve-containing conduit and method for producing it | |
| Noishiki et al. | Development and evaluation of a pliable biological valved conduit. Part I: preparation, biochemical properties, and histological findings | |
| EP1354515B1 (en) | Preserved tissue matrix of a hollow organ, in particular a blood vessel, method for its preparation and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180302 |
|
| RJ01 | Rejection of invention patent application after publication |